BMC Endocrine Disorders

Table 2 Efficacy endpoints at Week 24

From: A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin

Parameter	Omarigliptin N = 153	Placebo N = 153
HbA1c, %
Baseline	8.5 ± 0.8	8.6 ± 0.8
Week 24	7.7 ± 1.1	8.4 ± 1.1
Change from baseline^a	−0.67 (−0.84, −0.50)	−0.06 (−0.23, −0.12)
Change vs. placebo^b	−0.61^d (−0.85, −0.38)	–
FPG^c, mmol/L
Baseline	10.2 ± 2.3	10.2 ± 2.3
Week 24	8.9 ± 2.2	9.8 ± 2.0
Change from baseline^a	−1.1 (−1.5, −0.7)	−0.2 (−0.6, 0.2)
Change vs. placebo^b	−0.9^d (−1.4, −0.4)	–

Values are mean ± standard deviation unless otherwise noted
^aLeast squares (LS) mean (95% CI)
^bDifference in LS means (95% CI)
^cTo convert to mg/dL multiply mmol/L value by 18
^dp < 0.001

Back to article page

ISSN: 1472-6823

Contact us

General enquiries: journalsubmissions@springernature.com